Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Totus Medicines
BeOne Medicines
UNC Lineberger Comprehensive Cancer Center
Indiana University
BeOne Medicines
Washington University School of Medicine
"Oncostar" LLC
University of Colorado, Denver
Novartis
EMD Serono
Regor Pharmaceuticals Inc.
Eli Lilly and Company
Pfizer
MOMA Therapeutics
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Kivu Bioscience Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
AstraZeneca
BeOne Medicines
Incyte Corporation
Mersana Therapeutics
Cellectar Biosciences, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Providence Health & Services
National Cancer Institute (NCI)
Eli Lilly and Company
Iambic Therapeutics, Inc
Nammi Therapeutics Inc
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
ExpreS2ion Biotechnologies
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Boundless Bio, Inc.
Halda Therapeutics OpCo, Inc.
Dana-Farber Cancer Institute
Medical University of South Carolina
Novartis
Fate Therapeutics
Conjupro Biotherapeutics, Inc.